We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Moves -0.38%: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $44.11, moving -0.38% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.97%. Elsewhere, the Dow lost 2.32%, while the tech-heavy Nasdaq lost 2.78%.
Heading into today, shares of the drugmaker had gained 3.43% over the past month, outpacing the Medical sector's loss of 1.15% and the S&P 500's loss of 3.33% in that time.
Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be January 29, 2019. The company is expected to report EPS of $0.64, up 3.23% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.73 billion, up 0.18% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $3 per share and revenue of $53.40 billion. These results would represent year-over-year changes of +13.21% and +1.62%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.48% higher. PFE is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, PFE is holding a Forward P/E ratio of 14.77. This valuation marks a premium compared to its industry's average Forward P/E of 14.76.
It is also worth noting that PFE currently has a PEG ratio of 2.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 38, putting it in the top 15% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Moves -0.38%: What You Should Know
Pfizer (PFE - Free Report) closed the most recent trading day at $44.11, moving -0.38% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.97%. Elsewhere, the Dow lost 2.32%, while the tech-heavy Nasdaq lost 2.78%.
Heading into today, shares of the drugmaker had gained 3.43% over the past month, outpacing the Medical sector's loss of 1.15% and the S&P 500's loss of 3.33% in that time.
Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be January 29, 2019. The company is expected to report EPS of $0.64, up 3.23% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.73 billion, up 0.18% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $3 per share and revenue of $53.40 billion. These results would represent year-over-year changes of +13.21% and +1.62%, respectively.
Investors might also notice recent changes to analyst estimates for PFE. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.48% higher. PFE is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, PFE is holding a Forward P/E ratio of 14.77. This valuation marks a premium compared to its industry's average Forward P/E of 14.76.
It is also worth noting that PFE currently has a PEG ratio of 2.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 38, putting it in the top 15% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.